251 related articles for article (PubMed ID: 27470518)
21. Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity.
Ueda H; Hayashi H; Kudo K; Takeda M; Nakagawa K
Invest New Drugs; 2016 Dec; 34(6):797-799. PubMed ID: 27550238
[TBL] [Abstract][Full Text] [Related]
22. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.
Scheffler M; Di Gion P; Doroshyenko O; Wolf J; Fuhr U
Clin Pharmacokinet; 2011 Jun; 50(6):371-403. PubMed ID: 21553932
[TBL] [Abstract][Full Text] [Related]
23. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y
Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023
[TBL] [Abstract][Full Text] [Related]
24. A phase I study of volasertib combined with afatinib, in advanced solid tumors.
Machiels JP; Peeters M; Herremans C; Surmont V; Specenier P; De Smet M; Pilz K; Strelkowa N; Liu D; Rottey S
Cancer Chemother Pharmacol; 2015 Oct; 76(4):843-51. PubMed ID: 26349473
[TBL] [Abstract][Full Text] [Related]
25. Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
Soria JC; Baselga J; Hanna N; Laurie SA; Bahleda R; Felip E; Calvo E; Armand JP; Shepherd FA; Harbison CT; Berman D; Park JS; Zhang S; Vakkalagadda B; Kurland JF; Pathak AK; Herbst RS
Eur J Cancer; 2013 May; 49(8):1815-24. PubMed ID: 23490650
[TBL] [Abstract][Full Text] [Related]
26. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
Soria JC; Felip E; Cobo M; Lu S; Syrigos K; Lee KH; Göker E; Georgoulias V; Li W; Isla D; Guclu SZ; Morabito A; Min YJ; Ardizzoni A; Gadgeel SM; Wang B; Chand VK; Goss GD;
Lancet Oncol; 2015 Aug; 16(8):897-907. PubMed ID: 26156651
[TBL] [Abstract][Full Text] [Related]
27. Improved oral bioavailability and brain accumulation of afatinib due to dual inhibition of the efflux mechanisms of BCRP and Pgp transporters -What next?
Srinivas NR
Pharmacol Res; 2017 Sep; 123():143. PubMed ID: 28535973
[No Abstract] [Full Text] [Related]
28. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
[TBL] [Abstract][Full Text] [Related]
29. Clinical perspective of afatinib in non-small cell lung cancer.
Chen X; Zhu Q; Zhu L; Pei D; Liu Y; Yin Y; Schuler M; Shu Y
Lung Cancer; 2013 Aug; 81(2):155-61. PubMed ID: 23664448
[TBL] [Abstract][Full Text] [Related]
30. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
31. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.
Yang JC; Shih JY; Su WC; Hsia TC; Tsai CM; Ou SH; Yu CJ; Chang GC; Ho CL; Sequist LV; Dudek AZ; Shahidi M; Cong XJ; Lorence RM; Yang PC; Miller VA
Lancet Oncol; 2012 May; 13(5):539-48. PubMed ID: 22452895
[TBL] [Abstract][Full Text] [Related]
32. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Marquez-Medina D; Popat S
Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
[TBL] [Abstract][Full Text] [Related]
33. Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer.
De Pauw I; Wouters A; Van den Bossche J; Peeters M; Pauwels P; Deschoolmeester V; Vermorken JB; Lardon F
Pharmacol Ther; 2016 Oct; 166():71-83. PubMed ID: 27373506
[TBL] [Abstract][Full Text] [Related]
34. Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors.
Giordano P; Manzo A; Montanino A; Costanzo R; Sandomenico C; Piccirillo MC; Daniele G; Normanno N; Carillio G; Rocco G; Bianco R; Perrone F; Morabito A
Crit Rev Oncol Hematol; 2016 Jan; 97():143-51. PubMed ID: 26318094
[TBL] [Abstract][Full Text] [Related]
35. Clinical and preclinical pharmacokinetics of raltitrexed.
Clarke SJ; Beale PJ; Rivory LP
Clin Pharmacokinet; 2000 Dec; 39(6):429-43. PubMed ID: 11192475
[TBL] [Abstract][Full Text] [Related]
36. Clinical Pharmacokinetics and Pharmacodynamics of Cediranib.
Tang W; McCormick A; Li J; Masson E
Clin Pharmacokinet; 2017 Jul; 56(7):689-702. PubMed ID: 27943222
[TBL] [Abstract][Full Text] [Related]
37. A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Goss G; Hirte H; Miller WH; Lorimer IA; Stewart D; Batist G; Parolin DA; Hanna P; Stafford S; Friedmann J; Walsh W; Mathews S; Douglas L; Seymour LK
Invest New Drugs; 2005 Mar; 23(2):147-55. PubMed ID: 15744591
[TBL] [Abstract][Full Text] [Related]
38. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.
Solca F; Dahl G; Zoephel A; Bader G; Sanderson M; Klein C; Kraemer O; Himmelsbach F; Haaksma E; Adolf GR
J Pharmacol Exp Ther; 2012 Nov; 343(2):342-50. PubMed ID: 22888144
[TBL] [Abstract][Full Text] [Related]
39. Clinical analysis of patients treated with afatinib for advanced non-small cell lung cancer: A Nagano Lung Cancer Research Group observational study.
Wada Y; Koyama S; Kuraishi H; Miyahara T; Yoshiike F; Agatsuma T; Yamamoto R; Ono Y; Suzuki T; Hachiya T; Gomi D; Tateishi K; Hanaoka M; Koizumi T
Respir Investig; 2016 Nov; 54(6):462-467. PubMed ID: 27886858
[TBL] [Abstract][Full Text] [Related]
40. Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
Alshami J; Guiot MC; Owen S; Kavan P; Gibson N; Solca F; Cseh A; Reardon DA; Muanza T
Oncotarget; 2015 Oct; 6(32):34030-7. PubMed ID: 26423602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]